ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $16,332,925 | -77.4% | 1,103,576 | -70.8% | 0.06% | -80.6% |
Q3 2022 | $72,337,000 | +70.8% | 3,785,277 | +90.5% | 0.29% | +61.5% |
Q2 2022 | $42,352,000 | +29.5% | 1,987,431 | +17.1% | 0.18% | +37.7% |
Q1 2022 | $32,701,000 | -40.4% | 1,697,849 | -35.8% | 0.13% | -40.6% |
Q4 2021 | $54,840,000 | +15.2% | 2,644,177 | +32.7% | 0.22% | +4.8% |
Q3 2021 | $47,591,000 | +94.5% | 1,992,107 | +122.2% | 0.21% | +90.0% |
Q2 2021 | $24,463,000 | +92.5% | 896,400 | +104.1% | 0.11% | +86.4% |
Q1 2021 | $12,709,000 | -48.4% | 439,300 | -49.8% | 0.06% | -50.8% |
Q4 2020 | $24,619,000 | +1843.1% | 875,200 | +1923.3% | 0.12% | +1900.0% |
Q3 2020 | $1,267,000 | – | 43,256 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |